Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Gramont, A.
Right arrow Articles by Bedenne, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Gramont, A.
Right arrow Articles by Bedenne, L.

Journal of Clinical Oncology, Vol 15, 808-815, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

A de Gramont, JF Bosset, C Milan, P Rougier, O Bouche, PL Etienne, F Morvan, C Louvet, T Guillot, E Francois and L Bedenne
Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD), Hopital Saint-Antoine, Paris, France.

PURPOSE: This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer. PATIENTS AND METHODS: Of the 448 patients randomly assigned to treatment, 433 were assessable. Treatment A was a monthly regimen of intravenous (IV) LV 20 mg/m2 plus bolus 5-FU 425 mg/m2 for 5 days every 4 weeks. Treatment B was a bimonthly regimen of IV LV 200 mg/m2 as a 2- hour infusion followed by bolus 5-FU 400 mg/m2 and 22-hour infusion 5- FU 600 mg/m2 for 2 consecutive days every 2 weeks. Therapy was continued until disease progression. Second-line chemotherapy, which included 5-FU continuous infusion, was allowed in both arms. RESULTS: The response rates in 348 patients with measurable lesions were 14.4% (monthly regimen) and 32.6% (bimonthly regimen) (P = .0004). The median progression-free survival times were 22 weeks (monthly regimen) and 27.6 weeks (bimonthly regimen) (P = .0012). The median survival times were 56.8 weeks (monthly regimen) and 62 weeks (bimonthly regimen) (P = .067). Grade 3-4 toxicities occurred in 23.9% of patients in the monthly arm compared with 11.1% of those in the bimonthly arm (P = .0004). Patients in arm A more frequently experienced severe granulocytopenia (7.3% v 1.9%), diarrhea (7.3% v 2.9%), and mucositis (7.3% v 1.9%) than patients in arm B. CONCLUSION: The bimonthly regimen was more effective and less toxic than the monthly regimen and definitely increased the therapeutic ratio. However, there was no evidence of increased survival.


This article has been cited by other articles:


Home page
 JCOHome page
E. Gamelin, R. Delva, J. Jacob, Y. Merrouche, J. L. Raoul, D. Pezet, E. Dorval, G. Piot, A. Morel, and M. Boisdron-Celle
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., May 1, 2008; 26(13): 2099 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Haller, J. Cassidy, S. J. Clarke, D. Cunningham, E. Van Cutsem, P. M. Hoff, M. L. Rothenberg, L. B. Saltz, H.-J. Schmoll, C. Allegra, et al.
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
J. Clin. Oncol., May 1, 2008; 26(13): 2118 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Glimelius, H. Sorbye, L. Balteskard, P. Bystrom, P. Pfeiffer, K. Tveit, R. Heikkila, N. Keldsen, M. Albertsson, H. Starkhammar, et al.
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann. Onc., May 1, 2008; 19(5): 909 - 914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Twelves
Defining the Optimal Schedule of Drug Administration: Art or Science?
J. Clin. Oncol., April 10, 2008; 26(11): 1781 - 1782.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Pessino, S. Artale, S. Sciallero, A. Guglielmi, G. Fornarini, I.C. Andreotti, S. Mammoliti, D. Comandini, F. Caprioni, E. Bennicelli, et al.
First-line single-agent cetuximab in patients with advanced colorectal cancer
Ann. Onc., April 1, 2008; 19(4): 711 - 716.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Zalcberg, L. S. Rosen, E. Abdi, I. D. Davis, J. Gutheil, F. M. Schnell, A. Cesano, U. Gayko, M.-G. Chen, and S. Clarke
Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1386 - 1387.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. M. Pawlik, R. D. Schulick, and M. A. Choti
Expanding Criteria for Resectability of Colorectal Liver Metastases
Oncologist, January 1, 2008; 13(1): 51 - 64.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Hochster, W. Luo, E. C. Popa, B. T. Lyman, M. Mulcahy, P. A. Beatty, and A. B. Benson
Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (>= 75 years old) Patients With Colorectal Cancer: ECOG 1299
J. Clin. Oncol., December 1, 2007; 25(34): 5397 - 5402.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Becouarn, P. Senesse, S. Thezenas, E. Boucher, A. Adenis, L. Cany, J. H. Jacob, F. Cvitkovic, C. Montoto-Grillot, and M. Ychou
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer
Ann. Onc., December 1, 2007; 18(12): 2000 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-G. Kim, S. Y. Oh, H.-C. Kwon, S. Lee, J. H. Kim, S.-H. Kim, and H.-J. Kim
A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym103v1.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock
Drug Resistance and the Solid Tumor Microenvironment
J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. A. Hospers, C. J. A. Punt, M. E. Tesselaar, A. Cats, K. Havenga, J. W. H. Leer, C. A. Marijnen, E. P. Jansen, H. H. J. M. Van Krieken, T. Wiggers, et al.
Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I II Multicenter Study of the Dutch Colorectal Cancer Group
Ann. Surg. Oncol., October 1, 2007; 14(10): 2773 - 2779.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Andre, E. Quinaux, C. Louvet, P. Colin, E. Gamelin, O. Bouche, E. Achille, P. Piedbois, N. Tubiana-Mathieu, A. Boutan-Laroze, et al.
Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1
J. Clin. Oncol., August 20, 2007; 25(24): 3732 - 3738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. S. Siegel-Lakhai, J. H. Beijnen, W. L. Vervenne, H. Boot, M. Keessen, M. Versola, K. M. Koch, D. A. Smith, L. Pandite, D. J. Richel, et al.
Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
Clin. Cancer Res., August 1, 2007; 13(15): 4495 - 4502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. E. Haines
Questions About the Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol., July 1, 2007; 25(19): e24 - e25.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Murata and M. Moriyama
Isoleucine, an Essential Amino Acid, Prevents Liver Metastases of Colon Cancer by Antiangiogenesis
Cancer Res., April 1, 2007; 67(7): 3263 - 3268.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A.-R. Hanauske, J. Cassidy, J. Sastre, C. Bolling, R. J. Jones, A. Rakhit, S. Fettner, U. Brennscheidt, A. Feyereislova, and E. Diaz-Rubio
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 15, 2007; 13(2): 523 - 531.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Oncologist, January 1, 2007; 12(1): 38 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.
Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Gusella, G Crepaldi, C Barile, A Bononi, D Menon, S Toso, D Scapoli, L Stievano, E Ferrazzi, F Grigoletto, et al.
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer
Ann. Onc., November 1, 2006; 17(11): 1656 - 1660.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. Alberts
Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial
J. Clin. Oncol., July 20, 2006; 24(21): 3347 - 3353.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Hyodo, K. Shirao, T. Doi, K. Hatake, Y. Arai, K. Yamaguchi, T. Tamura, S. Takemiya, H. Takiuchi, K. Nakagawa, et al.
A Phase II Study of the Global Dose and Schedule of Capecitabine in Japanese Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 410 - 417.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Bevacizumab and {blacktriangledown}cetuximab for colorectal cancer
DTB, May 1, 2006; 44(5): 37 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Yamada, A. Ohtsu, N. Boku, Y. Miyata, Y. Shimada, T. Doi, K. Muro, M. Muto, T. Hamaguchi, K. Mera, et al.
Phase I/II Study of Oxaliplatin with Weekly Bolus Fluorouracil and High-Dose Leucovorin (ROX) As First-Line Therapy for Patients with Colorectal Cancer.
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 218 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. A. P. Hospers, M. Schaapveld, J. W. R. Nortier, J. Wils, A. van Bochove, R. S. de Jong, G. J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, et al.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C.-H. Kohne and G. Folprecht
On prejudice and facts and choices
Ann. Onc., February 1, 2006; 17(2): 185 - 187.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Twelves, S. Gollins, R. Grieve, and L. Samuel
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Ann. Onc., February 1, 2006; 17(2): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Tournigand, A. Cervantes, A. Figer, G. Lledo, M. Flesch, M. Buyse, L. Mineur, E. Carola, P.-L. Etienne, F. Rivera, et al.
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer--A GERCOR Study
J. Clin. Oncol., January 20, 2006; 24(3): 394 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Hata, H. Yamamoto, C. Y. Ngan, M. Koi, A. Takagi, B. Damdinsuren, M. Yasui, Y. Fujie, T. Matsuzaki, H. Hemmi, et al.
Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1585 - 1594.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Sakamoto, C. Hamada, M. Rahman, S. Kodaira, K. Ito, H. Nakazato, Y. Ohashi, and M. Yasutomi
An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer
Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 536 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujie, H. Yamamoto, C. Y. Ngan, A. Takagi, T. Hayashi, R. Suzuki, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, et al.
Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells
Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 453 - 463.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, N. Gebbia, G. Carteni, B. Agostara, G. Pezzella, L. Manzione, et al.
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale
J. Clin. Oncol., August 1, 2005; 23(22): 4866 - 4875.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-H. Kohne, E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M.P. Lutz, M. Lorenz, P. Reichardt, H. Ruckle-Lanz, N. Frickhofen, et al.
Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
J. Clin. Oncol., August 1, 2005; 23(22): 4856 - 4865.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Ducreux, M. Ychou, A. Laplanche, E. Gamelin, P. Lasser, F. Husseini, F. Quenet, F. Viret, J.-H. Jacob, V. Boige, et al.
Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 4881 - 4887.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Kelly and R. M. Goldberg
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
J. Clin. Oncol., July 10, 2005; 23(20): 4553 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Comella, B. Massidda, G. Filippelli, S. Palmeri, D. Natale, A. Farris, F. De Vita, F. Buzzi, S. Tafuto, L. Maiorino, et al.
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
Ann. Onc., June 1, 2005; 16(6): 878 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Wright, G. Morrison, P. Lin, G. D. Leonard, D. Nguyen, X. Guo, E. Szabo, J. L. Hopkins, J. P. Leguizamo, N. Harold, et al.
A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors
Clin. Cancer Res., June 1, 2005; 11(11): 4144 - 4150.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Meydan, I. Kundak, T. Yavuzsen, I. Oztop, S. Barutca, U. Yilmaz, and M. N. Alakavuklar
Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-up
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Venook
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Oncologist, April 1, 2005; 10(4): 250 - 261.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30.
[Abstract] [PDF]

Home page
 NEJMHome page
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487.
[Full Text] [PDF]

Home page
 JCOHome page
N. Kemeny, C. A. Garay, J. Gurtler, H. Hochster, P. Kennedy, A. Benson, D. Schwab Brandt, J. Polikoff, M. Wertheim, G. Shumaker, et al.
Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer
J. Clin. Oncol., December 1, 2004; 22(23): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al.
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al.
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
Ann. Onc., September 1, 2004; 15(9): 1330 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Lal, J. Dickson, D. Cunningham, I. Chau, A. R. Norman, P. J. Ross, C. Topham, G. Middleton, M. Hill, and J. Oates
A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor--Resistant Advanced Colorectal Cancer
J. Clin. Oncol., August 1, 2004; 22(15): 3023 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. S.-C. Chu, L. A. Hammond, G. Schwartz, L. Ochoa, S.-Y. Rha, L. Denis, K. Molpus, B. Roedig, S. P. Letrent, B. Damle, et al.
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
Clin. Cancer Res., August 1, 2004; 10(15): 4913 - 4921.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. J. Lee, T. M. Kim, S. J. Yu, D.-W. Kim, Y.-h. Joh, D.-Y. Oh, J. H. Kwon, T. Y. Kim, D. S. Heo, Y.-J. Bang, et al.
Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 400 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Mitry, J.-Y. Douillard, E. Van Cutsem, D. Cunningham, E. Magherini, D. Mery-Mignard, L. Awad, and P. Rougier
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials
Ann. Onc., July 1, 2004; 15(7): 1013 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Cals, O. Rixe, E. Francois, R. Favre, L. Merad, G. Deplanque, A. Laadem, P. Juin, J. M. Bereder, D. Bernardini, et al.
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
Ann. Onc., July 1, 2004; 15(7): 1018 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, et al.
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
N. Engl. J. Med., June 3, 2004; 350(23): 2343 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cassidy, J. Tabernero, C. Twelves, R. Brunet, C. Butts, T. Conroy, F. Debraud, A. Figer, J. Grossmann, N. Sawada, et al.
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., June 1, 2004; 22(11): 2084 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist, June 1, 2004; 9(3): 282 - 294.